

# WuXi Biologics

Global Solution Provider



## Newsletter March, 2021



**WuXi Biologics Achieve Record High 2020 Results Despite Challenging Year**

### Operations Update

Remote Pre-Approval Inspection Completed by EMA on WuXi Biologics' MFG4 Facility [Read More](#)

WuXi Biologics Receives GMP Certification from Brazil's ANVISA [Read More](#)

WuXi Biologics to Acquire CMAB and Form Strategic Partnership with CBC Group [Read More](#)

WuXi Biologics to Acquire Biologics DS and DP Manufacturing Facilities from Pfizer China [Read More](#)

WuXi Biologics to Acquire Drug Substance Facility in Wuppertal, Germany from Bayer [Read More](#)

WuXi Vaccines Achieves Weather-Tight

### Technical Content

[Antibody Drug Conjugates \(ADC\) Drug Development and Manufacturing Trends, Challenges and Solutions \(Webinar\)](#)

[Expediting Biologics Drug Development: Strategies to Accelerate Preclinical Development Timelines \(Webinar\)](#)

[Applications and Impact of CRISPR/Cas9 in Bioprocessing \(Podcast\)](#)

[Continuous Biomanufacturing Implementation – Using an Intensified and Integrated Bioprocess Platform \(White Paper\)](#)

[The Watershed Moment for ADCs has Arrived \(White Paper\)](#)

[Reducing Fill Risk in Drug Product Manufacture](#)

**Construction Milestone Despite COVID-19**  
[Read More](#)

**The World's Largest 36,000L  
Biomanufacturing Line Using Single-use  
Bioreactors Launches GMP Operation at  
WuXi Biologics** [Read More](#)

**GMP Inspection Completed by ANVISA at  
WuXi Biologics DS facility** [Read More](#)

## WuXi Bio Speed

**WuXi Vaccines Achieves Weather-Tight  
Construction Milestone Despite COVID-19**  
[Read More](#)

WuXi Biologics standardizes a  
remarkable 12 month “DNA to IND”  
timeline through its streamlined  
development platform  
[Read More](#)

**WuXi Biologics**  
Global Solution Provider

## Quarterly Regulatory Update Newsletter from WuXi Biologics



Our Regulatory Affairs team provides a  
quarterly summary of updates organized  
by agency and by topic. These updates  
support your efforts to stay current in our  
ever-changing regulatory environment.

[View Updates](#)

For more information - See this Podcast  
**The Challenge of Staying Current with  
Regulatory Changes – How one company is  
providing a solution**

**Utilizing New State-of-the-Art Systems and  
Platforms** (Podcast)

**New Flexible Bispecific Antibody Format  
Demonstrates Improved Therapeutic Properties  
And Manufacturability** (White Paper)

**Scale-Out Biomanufacturing – A Paradigm  
Change to Scale-Up** (White Paper)

## Partner News

**Exelixis Enters into Exclusive License  
Agreement with WuXi Biologics to  
Support Further Expansion of its Growing  
Oncology Biologics Pipeline** [Read More](#)

**WuXi Biologics Congratulates Vir  
Biotechnology on Positive Data from  
Phase 1 Trial of VIR-3434 for Chronic  
Hepatitis B Virus Infection** [Read More](#)

**WuXi Biologics, WuXi STA and  
Antengene Announce Collaboration to  
Advance Antibody-Drug Conjugate  
Candidate into Clinical Stage** [Read More](#)

**Oxford BioTherapeutics Designates  
Second Bispecific Antibody Program  
Leveraging WuXi Biologics' WuXiBody®  
Platform** [Read More](#)


**Tubulis Forms Strategic Partnership with  
WuXi Biologics and WuXi STA to Advance  
New Generation of Antibody-Drug  
Conjugates towards Clinical Evaluation**  
[Read More](#)

## Awards



**The Challenge of Staying Current  
with Regulatory Changes** – How  
one company is providing a solution

**Ken Chen**  
Senior Director, Regulatory Affairs



## WuXi Biologics Wins 2021 CMO Leadership Awards in All Six Core Categories

---

To read more about WuXi Biologics visit our [Newsletter Archive](#)

---